Welcome to our dedicated page for Igm Biosciences news (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on Igm Biosciences stock.
IGM Biosciences, Inc. (IGMS) generates news primarily through its clinical-stage biotechnology activities and corporate transactions. The company has described itself as focused on developing engineered IgM-based therapeutic antibodies, including T cell engaging IgM antibodies, for cancer and autoimmune and inflammatory diseases. Its updates often cover progress in clinical trials, strategic shifts in its pipeline, collaboration developments and significant corporate events.
News items have detailed the advancement of key product candidates such as imvotamab, a CD20 x CD3 bispecific IgM T cell engager antibody studied in autoimmune indications including rheumatoid arthritis, systemic lupus erythematosus and idiopathic inflammatory myopathies, and IGM‑2644, a CD38 x CD3 T cell engager antibody in development for autoimmune diseases. Other releases have described clinical studies of aplitabart (also referred to as IGM‑8444), a death receptor 5 agonist evaluated in combination regimens for metastatic colorectal cancer, along with enrollment milestones and trial design features.
Corporate news has included a strategic pivot to focus exclusively on autoimmunity, with an associated pipeline transformation and workforce changes, followed by a later decision to halt further development of imvotamab and IGM‑2644 for autoimmune diseases and to explore internal options and strategic alternatives. IGM Biosciences has also issued announcements about its exclusive worldwide collaboration agreement with Sanofi on IgM antibody agonists for immunology and inflammation targets and other collaborations with biotechnology partners.
A major development in the company’s news flow is the announcement of a definitive merger agreement under which Concentra Biosciences, LLC will acquire IGM Biosciences through a cash tender offer and subsequent merger, with IGM Biosciences becoming a wholly owned subsidiary of Concentra. For readers following IGMS, the news stream provides context on the evolution of the company’s IgM antibody pipeline, its strategic decisions and the transaction that led to its acquisition.
IGM Biosciences, a clinical-stage biotechnology company, announced a conference call on March 29, 2022, at 8:00 am ET to discuss a global collaboration with Sanofi. Interested parties can join by calling (866) 649-1996 domestically or (409) 217-8769 internationally, using conference ID 4983742. A live audio webcast will be available on their website under the Investors section, and a replay will be accessible for 90 days post-event. The company specializes in engineered IgM antibodies, aiming to overcome existing manufacturing challenges.
IGM Biosciences (Nasdaq: IGMS) announced progress in two Phase 1 clinical trials evaluating IGM-6268, an IgM monoclonal antibody for COVID-19. The trials in the U.S. and South Africa aim to assess the safety and preliminary efficacy of IGM-6268 administered intranasally. In vitro studies show IGM-6268 neutralizes the Omicron variant with an IC50 of 230 ng/mL, demonstrating superior potency against various SARS-CoV-2 variants compared to traditional IgG antibodies. Data from both trials is expected in mid-2022.
IGM Biosciences, Inc. (Nasdaq: IGMS) has announced that CEO Fred Schwarzer will present virtually at the Guggenheim 2022 Oncology Conference on February 10, 2022, at 1:00 p.m. EST. A live webcast will be available on the company's website, with a replay accessible for 90 days post-event. IGM Biosciences, based in Mountain View, California, focuses on developing engineered IgM antibodies, addressing challenges in therapeutic use since 2010. The company's proprietary IgM technology platform aims to yield advantages over traditional IgG antibodies.
IGM Biosciences, a clinical-stage biotechnology company, announced that CEO Fred Schwarzer will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 10:30 a.m. EST. The presentation will be accessible via a live webcast on the Company’s website, with a replay available for 30 days afterward. IGM Biosciences focuses on developing engineered IgM antibodies, addressing manufacturing and engineering challenges to enhance therapeutic applications compared to IgG antibodies.
IGM Biosciences, Inc. (IGMS) presented promising results from its Phase 1 trial of IGM-2323, a bispecific IgM antibody targeting CD20 x CD3, at the ASH Annual Meeting.
The trial involved 40 patients with advanced B-cell malignancies. No dose-limiting toxicities were observed, and a favorable safety profile was established. Notably, 50% of DLBCL patients and 66.67% of FL patients treated with 100 mg achieved complete responses.
Based on these results, IGM plans to initiate two Phase 2 studies to evaluate the efficacy of IGM-2323 in DLBCL and FL, which may lead to accelerated approval.
IGM Biosciences, Inc. (Nasdaq: IGMS) announced a grant agreement with the Bill & Melinda Gates Foundation to develop IgM and IgA antibodies aimed at malaria prevention. With over 200 million malaria cases and 400,000 deaths yearly, the initiative focuses on leveraging engineered antibodies for enhanced efficacy. Prior studies have shown engineered IgM antibodies could outperform IgG antibodies against infections. The partnership aims to evaluate these antibodies' effectiveness in animal models, highlighting IGM's commitment to addressing global health challenges.
IGM Biosciences, a clinical-stage biotechnology firm, will host a conference call on December 11, 2021, at 7:30 p.m. EST. This event follows the oral presentation of clinical data from its Phase 1 study of IGM-2323, a novel IgM antibody for B cell proliferative diseases, at the 63rd ASH Annual Meeting. The call will include IGM's management and Dr. Elizabeth Budde from City of Hope National Medical Center. Attendees can join by phone or via a live webcast on the company's investor website, with a replay available for 90 days.
IGM Biosciences (Nasdaq: IGMS), a clinical-stage biotechnology company, will participate in a fireside chat at the Jefferies London Healthcare Conference on November 17, 2021, at 1:40 p.m. GMT (8:40 a.m. EST). A live webcast of the event will be accessible on the Company’s website in the Investors section, with a replay available for 90 days thereafter. IGM focuses on developing engineered IgM antibodies to tackle challenges in therapeutic use, leveraging its proprietary technology platform since 2010.
IGM Biosciences, based in Mountain View, California, has announced its participation in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 2:00 p.m. EST. The event will include a fireside chat with management, and a live webcast will be available on the Company’s website. A replay of the webcast will be accessible for 90 days after the event. IGM Biosciences specializes in developing engineered IgM antibodies and has a proprietary technology platform aimed at advancing their therapeutic applications.
IGM Biosciences (Nasdaq: IGMS) announced a financial update for Q3 2021 and plans for clinical development. The company aims to initiate Phase 2 studies for IGM-2323 targeting diffuse large B-cell and follicular lymphoma, with data expected at the 2021 ASH Annual Meeting. IGM-8444 has successfully completed Phase 1 dose escalation without significant liver toxicity. Financially, the company reported a net loss of $44.2 million in Q3 2021, with cash reserves of $265.6 million. IGM expects full-year operational expenses between $175 million and $185 million.